Bleximenib

Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A.
== Pharmacology == Bleximenib is a selective inhibitor of menin preventing its interaction with the lysine methyltransferase KMT2A. The menin/KMT2A complex regulates gene expression in leukemia cells which keeps them in an immature state that is continually dividing.
== Clinical trials == Bleximenib is in phase 3 clinical trials for AML.
== References ==
Wikipedia contributors, "Bleximenib", Wikipedia, revision 1385145168, retrieved 21 November 2026, source, CC BY-SA 4.0.